Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis

RAGE Drives the Development of Glomerulosclerosis and Implicates Podocyte Activation in the Pathogenesis of Diabetic Nephropathy

Thoralf Wendt, Nozomu Tanji, Jiancheng Guo et al. · American Journal Of Pathology · 2003 · 593 citations · Full text

Medicine, Nephrology, Pathobiology +14

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

Yasuhiko Yamamoto, Ichiro Kato, Toshio Doi et al. · Journal of Clinical Investigation · 2001 · 474 citations · Full text

Medicine, Endocrinology, Nephrology +17

Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes

Aino Soro‐Paavonen, Anna M.D. Watson, Jiaze Li et al. · Diabetes · 2008 · 405 citations · Full text

Veterinary Medicine, Endocrinology, Pathobiology +14

Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen

Keizo Kanasaki, Sen Shi, Megumi Kanasaki et al. · Diabetes · 2014 · 368 citations · Full text

Medicine, Nephrology, Pharmacology +17

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic et al. · Diabetes Care · 2013 · 296 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17